These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 30656812)
1. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Faggioni M; Baber U; Chandrasekhar J; Sartori S; Weintraub W; Rao SV; Vogel B; Claessen B; Kini A; Effron M; Ge Z; Keller S; Strauss C; Snyder C; Toma C; Weiss S; Aquino M; Baker B; Defranco A; Bansilal S; Muhlestein B; Kapadia S; Pocock S; Poddar KL; Henry TD; Mehran R Catheter Cardiovasc Interv; 2019 Jul; 94(1):53-60. PubMed ID: 30656812 [TBL] [Abstract][Full Text] [Related]
2. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028 [TBL] [Abstract][Full Text] [Related]
3. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan. Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213 [TBL] [Abstract][Full Text] [Related]
4. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. Faggioni M; Baber U; Chandrasekhar J; Sartori S; Claessen BE; Rao SV; Vogel B; Effron MB; Poddar K; Farhan S; Kini A; Weintraub W; Toma C; Sorrentino S; Weiss S; Snyder C; Muhlestein JB; Kapadia S; Keller S; Strauss C; Aquino M; Baker B; Defranco A; Pocock S; Henry T; Mehran R Int J Cardiol; 2019 Jan; 275():31-35. PubMed ID: 30391067 [TBL] [Abstract][Full Text] [Related]
5. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database. Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197 [TBL] [Abstract][Full Text] [Related]
6. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. Scirica BM; Bergmark BA; Morrow DA; Antman EM; Bonaca MP; Murphy SA; Sabatine MS; Braunwald E; Wiviott SD J Am Coll Cardiol; 2020 Mar; 75(10):1095-1106. PubMed ID: 32164882 [TBL] [Abstract][Full Text] [Related]
7. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221 [TBL] [Abstract][Full Text] [Related]
8. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Chandrasekhar J; Baber U; Sartori S; Aquino M; Moalem K; Kini AS; Rao SV; Weintraub W; Henry TD; Vogel B; Ge Z; Muhlestein JB; Weiss S; Strauss C; Toma C; DeFranco A; Claessen BE; Keller S; Baker BA; Effron MB; Pocock S; Dangas G; Kapadia S; Mehran R Clin Res Cardiol; 2020 Jun; 109(6):725-734. PubMed ID: 31915997 [TBL] [Abstract][Full Text] [Related]
9. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. Chandrasekhar J; Baber U; Sartori S; Faggioni M; Aquino M; Kini A; Weintraub W; Rao S; Kapadia S; Weiss S; Strauss C; Toma C; Muhlestein B; DeFranco A; Effron M; Keller S; Baker B; Pocock S; Henry T; Mehran R Catheter Cardiovasc Interv; 2017 Mar; 89(4):629-637. PubMed ID: 27152497 [TBL] [Abstract][Full Text] [Related]
10. Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial. Lee JM; Jung JH; Park KW; Shin ES; Oh SK; Bae JW; Rhew JY; Lee N; Kim DB; Kim U; Han JK; Lee SE; Yang HM; Kang HJ; Koo BK; Kim S; Cho YK; Shin WY; Lim YH; Rha SW; Kim SY; Lee SY; Kim YD; Chae IH; Cha KS; Kim HS Trials; 2015 Sep; 16():409. PubMed ID: 26374625 [TBL] [Abstract][Full Text] [Related]
11. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States. Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386 [TBL] [Abstract][Full Text] [Related]
12. Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database. Sirker A; Kwok CS; Kontopantelis E; Johnson T; Freeman P; de Belder MA; Ludman P; Zaman A; Mamas MA Catheter Cardiovasc Interv; 2018 Oct; 92(4):659-665. PubMed ID: 29356278 [TBL] [Abstract][Full Text] [Related]
13. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233 [TBL] [Abstract][Full Text] [Related]
14. Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. Ge Z; Baber U; Claessen BE; Chandrasekhar J; Chandiramani R; Li SX; Sartori S; Kini AS; Rao SV; Weiss S; Henry TD; Kapadia S; Muhlestein B; Strauss C; Toma C; DeFranco A; Effron MB; Keller S; Baker BA; Pocock S; Dangas G; Mehran R J Thromb Thrombolysis; 2019 Jul; 48(1):42-51. PubMed ID: 30924052 [TBL] [Abstract][Full Text] [Related]
15. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial. Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S; Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries. Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336 [TBL] [Abstract][Full Text] [Related]
17. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573 [TBL] [Abstract][Full Text] [Related]
18. Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Chandrasekhar J; Baber U; Sartori S; Aquino M; Kini AS; Rao S; Weintraub W; Henry TD; Farhan S; Vogel B; Sorrentino S; Ge Z; Kapadia S; Muhlestein JB; Weiss S; Strauss C; Toma C; DeFranco A; Effron MB; Keller S; Baker BA; Pocock S; Dangas G; Mehran R Can J Cardiol; 2018 Mar; 34(3):319-329. PubMed ID: 29475531 [TBL] [Abstract][Full Text] [Related]
19. Tunehag KR; Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Gong Y; Kerensky RA; McDonough CW; Nguyen AB; Ortega-Paz L; Venkatesh S; Wang Y; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Cavallari LH; Lee CR J Am Heart Assoc; 2024 Jun; 13(12):e033791. PubMed ID: 38874073 [TBL] [Abstract][Full Text] [Related]